Advice
following a full submission assessed under the orphan equivalent process:
solriamfetol (Sunosi®) is accepted for restricted use within NHSScotland.
Indication under review: to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).
SMC restriction: for use in patients who have failed modafinil or have a contraindication or intolerance to modafinil.
Solriamfetol, compared with placebo, reduced excessive daytime sleepiness in adults with narcolepsy.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- solriamfetol (Sunosi)
- SMC ID:
- SMC2439
- Indication:
To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy (with or without cataplexy).
- Pharmaceutical company
- Jazz Pharmaceuticals
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 11 July 2022